AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, completed the acquisition of CinCor Pharma, a clinical-stage biopharmaceutical company, for $1.8bn. "We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved. CinCor is committed to ensuring a smooth transition of the development responsibilities to AstraZeneca once the acquisition is consummated. Thank you to all who have played, and will continue to play, essential roles in developing and evaluating baxdrostat as a potential novel treatment for cardiorenal diseases," Marc de Garidel, CinCor CEO.